Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

This study has been completed.
Information provided by (Responsible Party):
Mark Dewhirst, Duke University Medical Center Identifier:
First received: May 4, 2008
Last updated: June 1, 2015
Last verified: June 2015
Results First Received: August 1, 2011  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Transitional Cell Carcinoma of Bladder
Superficial Bladder Cancer
Interventions: Device: Hyperthermia System
Drug: Mitomycin C

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment Period: 09/2008-09/2010 Location: Urology and Radiation Oncology Clinics

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Mitomycin C With Hyperthermia and Recurrent Bladder Cancer Mitomycin C with Hyperthermia to Treat Recurrent Bladder Cancer

Participant Flow:   Overall Study
    Mitomycin C With Hyperthermia and Recurrent Bladder Cancer
Withdrawal by Subject                1 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Mitomycin C With Hyperthermia Mitomycin C and Hyperthermia

Baseline Measures
   Mitomycin C With Hyperthermia 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   7 
>=65 years   8 
[Units: Participants]
Female   2 
Male   13 
Race (NIH/OMB) 
[Units: Participants]
American Indian or Alaska Native   0 
Asian   0 
Native Hawaiian or Other Pacific Islander   0 
Black or African American   0 
White   15 
More than one race   0 
Unknown or Not Reported   0 
Region of Enrollment 
[Units: Participants]
United States   15 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Safety and Tolerability   [ Time Frame: During Treatment Phase average 6 weeks ]

2.  Secondary:   Median Recurrence Free-survival   [ Time Frame: Median follow-up 3.18 years ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information